Cormorant Asset Management
Overview
Cormorant Asset Management is a life sciences and healthcare focused investment firm that primarily invests in public and private biotechnology companies.
Year Founded
2013
AUM
$4.02B
Portfolio Companies
87
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Quince Therapeutics | Jun 2026 | Private Placement | Co-investor |
| Climb Bio, Inc. | May 2026 | Private Placement | Co-investor |
| Terremoto Biosciences | Apr 2026 | Series C | Co-investor |
| Candid Therapeutics, Inc. | Mar 2026 | PIPE | Co-investor |
| Faeth Therapeutics, Inc. | Feb 2026 | PIPE | Co-investor |
For institutional investors. Book with your work email.
Key People
Sarah Roxe
Director Of Investor Relations
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Cormorant Asset Management based?
Cormorant Asset Management is headquartered in Boston, Massachusetts, United States.
When was Cormorant Asset Management founded?
Cormorant Asset Management was founded in 2013.
How many portfolio companies does Cormorant Asset Management have?
Cormorant Asset Management has 87 portfolio companies in Caplight's dataset.
What are some companies in Cormorant Asset Management's portfolio?
Recent investments visible on Caplight include Quince Therapeutics, Climb Bio, Inc., Terremoto Biosciences, Candid Therapeutics, Inc., Faeth Therapeutics, Inc..
What was Cormorant Asset Management's most recent investment?
Cormorant Asset Management's most recent investment on Caplight was in Quince Therapeutics in 2026.
What sectors does Cormorant Asset Management focus on?
Cormorant Asset Management focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Frontier & Industrial Tech, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Cormorant Asset Management focus on?
Cormorant Asset Management typically invests at the Mid stage.
What is Cormorant Asset Management's AUM?
Cormorant Asset Management's assets under management are estimated between $2.1B and $4.0B.